Hi everyone
This is my first post here. I have found really helpful advice reading this forum.
My dad is a 64 year old male from India. Here’s his history:
In 2014, my father is having CA prostate. Radical prostatectomy done in June 13 with histopathology of T3 N1 M0 disease (Gleason 4+4, extraprostatic extension with clear margins , no SV involved and one periprostatic bed in positive). Over a period of 3 years his PSA rose to .2 from .04 and he underwent IMRT 33 cycles in October, 2016. His pre-RT PSMA scan which was done in Sep 2016 was normal. In January 2017 surprisingly his PSA rose to 0.9 from one lab, and to 1.8 from another lab. He was diagnosed to have a small peanut size mets in right subtrochanteric region of femur. Has been advised adt plus rt ( 10 sittings). The PSA reading was 2.8.
Since then RT and ADT, he has been on ADT (zoladex, every three months) since Feb 2017. His PSA has stable around <0.008ng/mL.
On November 8, 2019, his PSA rose to 0.032 ng/mL. On dec 18, his PSA is 0.064 ng/mL.
We are seeing a couple of docs in the US, but since parents have to travel it makes it a less frequent visit.
We have the following questions:
1. At what frequency should we continue to do the PSA test?
2. Would a scan help? If not, at what point would it help? We are thinking MRI, bone scan, PSMA PET.
3. Should zoladex be continued? His last dose is due in February. ( three year ADT)
4. What other drugs would make sense here, and at what point? We are thinking about Zytiga, enzalutamide and darolutamide.
5. Would gene testing be useful at this time for brca? What about a PSMA scan? I’m asking for targeted therapies at this stage like Lu-177, and parp inhibitors.
6. Any other recommendations on best course of action?
We are talking with dr. Eleni at Md Anderson and dr small at UCSF. The current consensus seems to be to get a pattern for the next few readings (3-4), establish a psa doubling time. The doubling time will then inform our intervention.